SCHEMBL18991797

SCHEMBL18991797

CC(C)(C)OC(=O)NCCCn1cc(-c2ccc(OCC(ON3C(=O)c4ccccc4C3=O)C(=O)O)cc2)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 2/20 0.39
▸ MMP3 P08254 2/20 0.39
▸ MMP9 P14780 2/20 0.39
▸ MMP13 P45452 2/20 0.39
▸ SUCNR1 Q9BXA5 8/20 0.39
▸ MALT1 Q9UDY8 1/20 0.37
▸ PDPK1 O15530 1/20 0.37
▸ CCNB2 O95067 1/20 0.37
▸ PRKCB P05771 1/20 0.37
▸ CDK1 P06493 1/20 0.37
▸ LYN P07948 1/20 0.37
▸ CCNB1 P14635 1/20 0.37
▸ CCNA2 P20248 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ RPS6KA3 P51812 1/20 0.37
▸ CCNA1 P78396 1/20 0.37
▸ CCNB3 Q8WWL7 1/20 0.37
▸ MMP1 P03956 1/20 0.37
▸ DRD2 P14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20566016 1.00 MMP2 (0.39) MMP2MMP3MMP9MMP13SUCNR1
SCHEMBL18991513 0.94 MMP2 (0.38) MMP2MMP3MMP9MMP13SUCNR1
SCHEMBL29360136 0.94 MMP2 (0.38) MMP2MMP3MMP9MMP13SUCNR1
SCHEMBL18991515 0.94 MMP2 (0.38) MMP2MMP3MMP9MMP13SUCNR1
SCHEMBL20566482 0.90 FEN1 (0.40) MALT1PDPK1CCNB2PRKCBCDK1
SCHEMBL20566483 0.90 FEN1 (0.40) MALT1PDPK1CCNB2PRKCBCDK1
SCHEMBL20567228 0.90 PDCD1 (0.37) SUCNR1MALT1PDPK1CCNB2PRKCB
SCHEMBL20567229 0.90 PDCD1 (0.37) SUCNR1MALT1PDPK1CCNB2PRKCB
SCHEMBL23827383 0.89 SCD (0.39) SUCNR1MALT1PDPK1CCNB2PRKCB
SCHEMBL23827381 0.89 SCD (0.39) SUCNR1MALT1PDPK1CCNB2PRKCB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11230543-B2 Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections MERCK SHARP & DOHME CORP. (US) 2022-01-25 — — US disclosed
EP-3390357-B1 BIARYL MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME (US) 2021-11-10 — — EP disclosed
US-20200361928-A1 BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME CORP. (US) 2020-11-19 — — US disclosed
US-20180339983-A1 BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME CORP. (US) 2018-11-29 — — US disclosed
EP-3390357-A1 BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS Merck Sharp & Dohme Corp. (US) 2018-10-24 — — EP disclosed
WO-2017106064-A1 BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME CORP. (US) 2017-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180339983-A1 BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS BMX, BTK, ABCB11 MMP2 717/4885MMP3 1279/4885MMP9 887/4885
US-11230543-B2 Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections SQLE, ABCB11, BMX MMP2 693/4885MMP3 1292/4885MMP9 1057/4885
US-20200361928-A1 BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS ABCB11, SQLE, BMX MMP2 624/4885MMP3 1282/4885MMP9 1052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback